Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study

Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study

Abstract Background Chronic kidney disease–associated pruritus (CKD-aP) can negatively impact quality of life and survival among patients receiving maintenance hemodialysis. Difelikefalin, a selective κ-opioid receptor agonist, is the first medication approved for treatment of moderate-to-severe CKD...

Full description

Saved in:
Bibliographic Details
Main Authors: Linda H. Ficociello, Rachel Lasky, Hans-Juergen Arens, Despina Ruessmann, Michael S. Anger
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Nephrology
Subjects:
Chronic kidney disease–associated pruritus
Difelikefalin
Hemodialysis
Symptoms
Online Access:https://doi.org/10.1186/s12882-025-04074-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12882-025-04074-7

Similar Items